Speculative M&A Transaction Analysis, page-631

@IndexInvestor this is a serious problem and one I run into all the time when talking about RAC and Zantrene. In my opinion we would have a higher SP today if we had a drug that worked in only 1% of small cell lung cancers. The potential just sounds too good to be true - you are telling me you have a clinical proven non-toxic drug that works in basically 15-20% of every cancer, but it was just used the wrong way in the past and you have found the reason why! Pull the other one.

We are in a similar situation to what happened with the immune therapy drugs before the first clinical trial results showed what a breakthrough they were - the industry and investors considered them worthless (Merck was giving away Keytruda for nothing until BMS’s result came out). While I can’t tell you if Zantrene will succeed or fail as an FTO inhibitor, I can tell you that the market often gets true breakthroughs completely wrong. The average small investor who has put in 20 hours of research into RAC is far better informed about Zantrene’s potential than any professional investor I have ever spoken to. Such is the biotech industry